Novartis AG said Tuesday that a phase 3 study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer met both key endpoints and overall radiographic survival without improvement.
Switzerland’s leading pharmaceutical company said it plans to make regulatory claims in the US and EU this year.
“Patients with metastatic prostate cancer who have anti-sputum cancer have less than 5 in 6 years survival and need new treatment options. This innovative data confirms our belief in the potential of 177Lu-PSMA- 617 to repeat outcomes for these patients through precision phenotypic treatment, ”said Head of Global Drug Development and Chief Medical Officer John Tsai.
Novartis said 177Lu-PSMA-617 is a radioligand treatment for metastatic castration-resistant prostate cancer, a type of precision cancer treatment that combines target combination with therapeutic radioisotope.
Write to Mauro Orru at [email protected]; @ MauroOrru94